Home Newsfeeds Baird Maintains Outperform on PagerDuty, Lowers Price Target to $35

Baird Maintains Outperform on PagerDuty, Lowers Price Target to $35

Baird analyst Rob Oliver maintains PagerDuty (NYSE:PD) with a Outperform and lowers the price target from $40 to $35.

byBenzinga Newsdesk

September 2, 2022

1 minute read

Baird analyst Rob Oliver maintains PagerDuty (NYSE:PD) with a Outperform and lowers the price target from $40 to $35.

Piper Sandler Downgrades Bank of America: What Investors Need To Know

By AJ Fabino

January 17, 2:03 PM

Bank of America Corp (NYSE: BAC) is facing some uncertainty for its future financial performance, leading analysts at Piper Sandler to downgrade the stock.

BAC

News

U.S. Treasury’s Yellen Says Closely Monitoring U.S. Financial Sector Amid Increased Global Market Volatility; To Date, U.S. Financial System Has Not Been A Source Of Economic Instability, Remains Resilient

By Benzinga Newsdesk

October 24, 11:05 AM

- Reuters Citing Prepared Remarks To SIFMA Annual Meeting

SPY

Bitcoin ‘FOMO’ To Push Prices To A ‘Different Level’: Mark Yusko

By Murtuza Merchant

April 22, 12:21 PM

Morgan Creek Capital’s founder Mark Yusko on Monday said a wave of “fear of missing out” (FOMO) is on the horizon for Bitcoin (CRYPTO:

BTC

FDA
News

FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 For Treatment Of Paroxysmal Nocturnal Hemoglobinuria

By Benzinga Newsdesk

July 29, 8:45 AM

Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). OMS906 targets

OMER

Baird Maintains Outperform on PagerDuty, Lowers Price Target to $35

Related Posts

Piper Sandler Downgrades Bank of America: What Investors Need To Know

U.S. Treasury’s Yellen Says Closely Monitoring U.S. Financial Sector Amid Increased Global Market Volatility; To Date, U.S. Financial System Has Not Been A Source Of Economic Instability, Remains Resilient

Bitcoin ‘FOMO’ To Push Prices To A ‘Different Level’: Mark Yusko

FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 For Treatment Of Paroxysmal Nocturnal Hemoglobinuria